SG11201510210XA - Methods for detecting prostate cancer - Google Patents
Methods for detecting prostate cancerInfo
- Publication number
- SG11201510210XA SG11201510210XA SG11201510210XA SG11201510210XA SG11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA SG 11201510210X A SG11201510210X A SG 11201510210XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- prostate cancer
- detecting prostate
- detecting
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013902141A AU2013902141A0 (en) | 2013-06-13 | Method for detecting prostate cancer | |
PCT/AU2014/000612 WO2014197937A1 (en) | 2013-06-13 | 2014-06-13 | Methods for detecting prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201510210XA true SG11201510210XA (en) | 2016-01-28 |
Family
ID=52021494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201510210XA SG11201510210XA (en) | 2013-06-13 | 2014-06-13 | Methods for detecting prostate cancer |
Country Status (7)
Country | Link |
---|---|
US (3) | US20160130661A1 (en) |
EP (2) | EP3800266A1 (en) |
JP (1) | JP6696896B2 (en) |
CN (1) | CN105658810B (en) |
AU (1) | AU2014280846B2 (en) |
SG (1) | SG11201510210XA (en) |
WO (1) | WO2014197937A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4036118A1 (en) | 2013-08-01 | 2022-08-03 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
CA3004794A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
EP3409772B1 (en) | 2016-01-29 | 2023-06-28 | National University Corporation Hokkaido University | Intracellular substance transport system and use thereof |
CN106282374A (en) * | 2016-09-23 | 2017-01-04 | 北京致成生物医学科技有限公司 | FAM13AOS is as molecular marked compound and the application thereof detecting carcinoma of prostate |
CN106319070A (en) * | 2016-09-28 | 2017-01-11 | 北京致成生物医学科技有限公司 | Application of NEURL1B in preparation of product for diagnosing prostatic carcinoma |
CN106544430A (en) * | 2016-11-04 | 2017-03-29 | 叶伟亮 | A kind of molecular marked compound of detection carcinoma of prostate and its application |
BR112019023898A2 (en) | 2017-05-16 | 2020-06-09 | Five Prime Therapeutics Inc | method for treatment of gastric cancer, use of an antibody and composition |
CA3068167A1 (en) * | 2017-06-23 | 2018-12-27 | Anette Weyergang | Diagnosis and treatment of cancer |
CN107630091B (en) * | 2017-09-20 | 2021-02-02 | 南方医科大学 | Application of Myosin1b gene or protein |
MX2020008702A (en) * | 2018-02-22 | 2020-09-25 | Liquid Biopsy Res Llc | Methods for prostate cancer detection and treatment. |
WO2020236998A2 (en) * | 2019-05-21 | 2020-11-26 | University Of Massachusetts | Genetic amplified tumor homing nanoparticles and compositions and methods thereof |
CN114641690A (en) * | 2019-09-03 | 2022-06-17 | 远景科学私人有限公司 | Methods for confirming, detecting and assessing prostate cancer progression and related treatments |
JP7479504B2 (en) | 2020-04-23 | 2024-05-08 | ニュー ライフ メディシン テクノロジー カンパニー リミテッド | Methods Related to Diagnosis of Prostate Cancer |
CN114316018A (en) * | 2021-11-26 | 2022-04-12 | 江南大学 | FGF21 protein analogue and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US20040038240A1 (en) * | 2001-07-13 | 2004-02-26 | Akhouri Sinha | Method and materials for assessing cancer aggressiveness |
EP1646426A2 (en) * | 2003-07-10 | 2006-04-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Appl proteins as rab5 effectors |
US7838249B2 (en) * | 2006-11-29 | 2010-11-23 | The Board Of Regents Of The University Of Oklahoma | Assays for rab5 activity |
KR101041308B1 (en) * | 2009-06-09 | 2011-06-14 | 성균관대학교산학협력단 | A composition for anticancer comprising appl1 inhibitor and a method for screening regulators of interaction between appl1 and egfr |
EP2776465A1 (en) * | 2011-11-09 | 2014-09-17 | Alper Biotech, Llc | Monoclonal antibodies against serotransferrin antigens, and uses therefor |
-
2014
- 2014-06-13 JP JP2016518800A patent/JP6696896B2/en active Active
- 2014-06-13 EP EP20193330.6A patent/EP3800266A1/en active Pending
- 2014-06-13 EP EP14810393.0A patent/EP3008210B1/en active Active
- 2014-06-13 WO PCT/AU2014/000612 patent/WO2014197937A1/en active Application Filing
- 2014-06-13 SG SG11201510210XA patent/SG11201510210XA/en unknown
- 2014-06-13 CN CN201480040747.8A patent/CN105658810B/en active Active
- 2014-06-13 AU AU2014280846A patent/AU2014280846B2/en active Active
- 2014-06-13 US US14/897,612 patent/US20160130661A1/en not_active Abandoned
-
2018
- 2018-01-23 US US15/794,270 patent/US11261496B2/en active Active
-
2022
- 2022-01-19 US US17/579,355 patent/US20220154292A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105658810B (en) | 2020-08-21 |
AU2014280846A1 (en) | 2015-12-24 |
JP2016527483A (en) | 2016-09-08 |
CN105658810A (en) | 2016-06-08 |
AU2014280846B2 (en) | 2020-11-05 |
US20160130661A1 (en) | 2016-05-12 |
WO2014197937A1 (en) | 2014-12-18 |
US11261496B2 (en) | 2022-03-01 |
EP3008210A1 (en) | 2016-04-20 |
EP3800266A1 (en) | 2021-04-07 |
EP3008210A4 (en) | 2017-05-17 |
US20180119229A1 (en) | 2018-05-03 |
US20220154292A1 (en) | 2022-05-19 |
JP6696896B2 (en) | 2020-05-20 |
EP3008210B1 (en) | 2020-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223552A1 (en) | Combination therapies for cancer | |
HK1217218A1 (en) | Biomarkers for colorectal cancer | |
HK1214652A1 (en) | Methods and compositions for detecting pancreatic cancer | |
SG11201510210XA (en) | Methods for detecting prostate cancer | |
IL246067A0 (en) | Prostate cancer classification | |
HK1220155A1 (en) | Methods for treating cancer | |
SG11201603050TA (en) | Methods for treating cancers | |
LU92173B1 (en) | Distance determination method | |
HK1213297A1 (en) | Compositions and methods for detecting and determining a prognosis for prostate cancer | |
IL233803A0 (en) | Monocyte biomarkers for cancer detection | |
EP2876447A4 (en) | Method for detecting cancer | |
EP2986326A4 (en) | Methods for detecting cancer metastasis | |
HK1220253A1 (en) | Methods of detecting prostate cancer | |
HK1213634A1 (en) | Methods of detecting cancer | |
GB201322800D0 (en) | Prostate cancer biomarkers | |
HUE043162T2 (en) | Method for detecting cancer | |
HK1216779A1 (en) | Predictive biomarker for cancer therapy | |
IL240319A (en) | Rapid detection | |
EP2985605A4 (en) | Method for detecting colon cancer | |
HK1220356A1 (en) | Novel therapy for prostate carcinoma | |
HUE048625T2 (en) | Methods for treating cancer | |
EP3033617A4 (en) | Biomarkers for prostate cancer | |
AU2013902141A0 (en) | Method for detecting prostate cancer | |
GB201306394D0 (en) | Cancer biomarker | |
GB201300369D0 (en) | Biomarker panel for prostate cancer |